MARKET

OTLKW

Outlook Therapeutics Inc
OTLKW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.2941
0.0670
1.149
-
OUTLOOK THERAPEUTICS ANNOUNCES PRICING OF $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 2d ago
Outlook Therapeutics director Randy H. Thurman reports purchase of 5,000 common shares for $2,145
PUBT · 3d ago
Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520
PUBT · 3d ago
BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment
Reuters · 5d ago
OUTLOOK THERAPEUTICS INC - TO RESUBMIT ONS-5,010/LYTENAVA BLA IN JUNE 2026
Reuters · 5d ago
OUTLOOK THERAPEUTICS INC - FDA GRANTS APPEAL FOR OUTLOOK THERAPEUTICS' ONS-5,010/LYTENAVA
Reuters · 5d ago
Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review
PUBT · 5d ago
OUTLOOK THERAPEUTICS INC <OTLK.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 05/18 10:45
More

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLKW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLKW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLKW stock methods without spending real money on the virtual paper trading platform.